Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15713422 | 1.00 | CA1 (0.39) | CA1CA2CA4TRPA1TRPM8 | |
| SCHEMBL21935366 | 0.81 | CA1 (0.39) | CA1CA2CA4 | |
| SCHEMBL21935393 | 0.81 | CA1 (0.39) | CA1CA2CA4 | |
| SCHEMBL18030226 | 0.79 | CA1 (0.37) | CA1CA2CA4 | |
| SCHEMBL24589002 | 0.77 | — | — | |
| SCHEMBL24588939 | 0.77 | — | — | |
| SCHEMBL24588935 | 0.77 | — | — | |
| SCHEMBL24589003 | 0.77 | — | — | |
| SCHEMBL18236385 | 0.77 | — | — | |
| SCHEMBL15114886 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643718-B1 | HETEROCYCLIC COMPOUND AND ITS USE AS POSITIVE ALLOSTERIC MODULATOR OF THE CHOLINERGIC MUSCARINIC M1 RECEPTOR. | TAKEDA PHARMACEUTICALS CO (JP) | 2023-07-26 | — | — | EP | disclosed |
| EP-3489237-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3643718-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3489237-A1 | 4-AZAINDOLE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-20180208593-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-9315494-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-19 | — | — | US | disclosed |
| WO-2015049574-A1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208593-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | CA1 2254/4885CA2 4384/4885CA4 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.